RxDoctor Payments Data

Stacey Brown-Brocklehurst, MD

Sports Medicine · Wheeling, WVNPI 1427233634

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Novo Nordisk at 27.2% of the total. Reporting peaked in 2019 at $105 and has fallen 81.0% since, to $20 in 2021. That places this record below the midpoint for sports medicine clinicians in WV, where the typical reported total is $288.

$195in general payments, 2019–2025

Across 13 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$53
  • Daiichi Sankyo Inc.$31
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$26
  • Edwards Lifesciences$26
  • Amarin Pharma, Inc.$25
  • Amgen$20
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$195 in reported general payments places this provider in the 45th percentile of 25 sports medicine providers in West Virginia.

See all sports medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$72,236
Medicare patients
290
Services billed
1,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$132,731
TrulicityDulaglutide32$42,506
EliquisApixaban32$37,259
XareltoRivaroxaban34$30,443
JardianceEmpagliflozin24$30,363
JanuviaSitagliptin Phosphate19$21,336
MounjaroTirzepatide12$12,169
Tresiba Flextouch U-100Insulin Degludec16$9,850
Insulin Lispro Kwikpen U-100Insulin Lispro11$2,331
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,022
Levothyroxine Sodium205$1,902
Albuterol Sulfate HfaAlbuterol Sulfate53$1,863
Ezetimibe-SimvastatinEzetimibe/Simvastatin12$1,858
Atorvastatin Calcium204$1,815
Lisinopril223$1,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$132,731110 claims
Johnson & JohnsonXarelto$15$30,44334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 25 sports medicine providers in West Virginia.

Other sports medicine in Wheeling

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →